Blog

Rahul Banerjee: Excited to speak with ASTCT about what’s new at Tandem25

Rahul Banerjee/X

Feb 13, 2025, 07:37

Rahul Banerjee: Excited to speak with ASTCT about what’s new at Tandem25

Rahul Banerjee, Assistant professor at Fred Hutchinson Cancer Center at the University of Washington, reshared a post by ASTCT on X, adding:

“Excited to speak with Shernan Holtan, CancerNetwork, ASTCT about what’s new at Tandem25!

Twitter spaces at 2pm HST = 4pm PST = 7pm EST.

For me, I’m most excited about LBA1 – a BMT CTN study of CAR-T as a post-ASCT chaser in Multiple myeloma being presented on Saturday by Al Garfall!”

Quoting ASTCT‘s post:

“Join the Cancer Survivor Net and ASTCT collaborative space with Rahul Banerjee and Shernan Holtan on Wednesday, February 12th at 7pm/ET or 2pm/HST focusing on CAR-T and transplantation at Tandem25.”

Al Garfall ASTCT cancer Cancer Survivor Net CancerNetwork CAR-T fight against cancer Fred Hutchinson Cancer Center Global fight against cancer OncoDaily Oncology Rahul Banerjee Shernan Holtan Tandem25 University of Washington

VERITAC-2 Trial Update: Vepdegestrant Meets Primary Endpoint in ESR1-Mutant Breast Cancer

New Paper Alert: HARMONi-2 study of Ivonescimab vs pembrolizumab for PD-L1-positive non-small cell lung cancer

We are thrilled to welcome Dr. Jasmine Kamboj to the OncoDaily Editorial Board!

Oncologist Near Me – Fedro Alessandro Peccatori: Leading Expert in Gynecological Oncology

MATTERHORN trial - FLOT plus durvalumab will become the new standard of care in the preoperative setting for gastroesophageal cancer

Special Coverage